Literature DB >> 6978274

Serum inhibitors of leukocyte chemotaxis in Crohn's disease and ulcerative colitis.

J M Rhodes, B J Potter, D J Brown, D P Jewell.   

Abstract

Studies were undertaken to determine the incidence and nature of serum chemotaxis inhibitors in patients with Crohn's disease and ulcerative colitis. Sera from patients with active Crohn's disease were shown to contain chemotactic factor-directed inhibitory activity. The molecular size of the inhibitor estimated by gel filtration is similar to the 7S gamma-globulins and it is precipitable by 40% ammonium sulfate. Less marked inhibitory activity is present in the same fractions of sera from patients with ulcerative colitis and from healthy controls, suggesting that it represents increased activity of one or more normal serum globulins. Leukocyte-directed serum inhibitors have also been demonstrated in patients with Crohn's disease and ulcerative colitis, particularly in patients with active disease. In Crohn's disease the presence of serum chemotactic factor inhibitors may explain the diminished chemotaxis of neutrophils into skin window chambers reported previously. The inhibitors are nonspecific and are probably secondary to the disease state but may have some bearing on the nature of the mucosal inflammation.

Entities:  

Mesh:

Substances:

Year:  1982        PMID: 6978274

Source DB:  PubMed          Journal:  Gastroenterology        ISSN: 0016-5085            Impact factor:   22.682


  13 in total

1.  Impaired neutrophil function in intestinal lymphangiectasia.

Authors:  R P Bolton; K L Cotter; M S Losowsky
Journal:  J Clin Pathol       Date:  1986-08       Impact factor: 3.411

2.  Familial occurrence of complement dysfunction in Crohn's disease: correlation with intestinal symptoms and hypercatabolism of complement.

Authors:  J Elmgreen; H Both; V Binder
Journal:  Gut       Date:  1985-02       Impact factor: 23.059

3.  'Conversion' from ulcerative colitis to Crohn's disease associated with corticosteroid treatment.

Authors:  A D Dwarakanath; J Nash; J M Rhodes
Journal:  Gut       Date:  1994-08       Impact factor: 23.059

Review 4.  Macrophage activation, chronic inflammation and gastrointestinal disease.

Authors:  A R Tanner; M J Arthur; R Wright
Journal:  Gut       Date:  1984-07       Impact factor: 23.059

5.  Subnormal activation of phagocytes by complement in chronic inflammatory bowel disease? Neutrophil chemotaxis to complement split product C5a.

Authors:  J Elmgreen
Journal:  Gut       Date:  1984-07       Impact factor: 23.059

6.  Motility of neutrophils and monocytes in Crohn's disease and ulcerative colitis.

Authors:  J M Rhodes; D P Jewell
Journal:  Gut       Date:  1983-01       Impact factor: 23.059

7.  In vivo assessment of granulocyte migration to diseased bowel in Crohn's disease.

Authors:  S H Saverymuttu; A M Peters; J P Lavender; V S Chadwick; H J Hodgson
Journal:  Gut       Date:  1985-04       Impact factor: 23.059

Review 8.  Innate immunity in inflammatory bowel disease: a disease hypothesis.

Authors:  D J B Marks; A W Segal
Journal:  J Pathol       Date:  2008-01       Impact factor: 7.996

9.  Potential role of microorganisms isolated from periodontal lesions in the pathogenesis of inflammatory bowel disease.

Authors:  T E Van Dyke; V R Dowell; S Offenbacher; W Snyder; T Hersh
Journal:  Infect Immun       Date:  1986-09       Impact factor: 3.441

Review 10.  Crohn's disease: an immune deficiency state.

Authors:  Daniel J B Marks; Farooq Z Rahman; Gavin W Sewell; Anthony W Segal
Journal:  Clin Rev Allergy Immunol       Date:  2010-02       Impact factor: 8.667

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.